p300/CBP inhibition enhances the efficacy of programmed death-ligand 1 blockade treatment in prostate cancer

Jinghui Liu(University of Kentucky), Xiaoqi Liu(University of Kentucky), Yifan Kong(University of Kentucky), Eun Y. Lee(University of Kentucky), Lijun Cheng(Taizhou Central Hospital), Karrie L. Jones(University of Kentucky), Xiongjian Rao(University of Kentucky), Daheng He(University of Kentucky), Chaohao Li(University of Kentucky), Jinpeng Liu(University of Kentucky), Zhuangzhuang Zhang(University of Kentucky), Changkun Huang(Central South University), Dana Napier(University of Kentucky), Chi Wang(University of Kentucky), Yanquan Zhang(University of Kentucky)
Oncogene
March 23, 2020
Cited by 114


Related Papers